Evidence map›Paper›PMID 41281477›Full record

ArticleWorld journal of gastrointestinal oncology2025

Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation.

Bai-Guo Xu, Xue Zhang, Fang Liu, Feng-Hui Li, Xu Zhang, Hui-Ling Xiang, Jing Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bai-Guo XuDepartment of Gastroenterology and Hepatopathy, The Central Hospital of Tianjin University, Tianjin 300170, China.
Xue ZhangDepartment of Gastroenterology and Hepatopathy, The Central Hospital of Tianjin University, Tianjin 300170, China.
Fang LiuDepartment of Gastroenterology and Hepatopathy, The Central Hospital of Tianjin University, Tianjin 300170, China.
Feng-Hui LiDepartment of Gastroenterology and Hepatopathy, The Central Hospital of Tianjin University, Tianjin 300170, China.
Xu ZhangDepartment of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Tianjin 300170, China.
Hui-Ling XiangDepartment of Gastroenterology and Hepatopathy, The Central Hospital of Tianjin University, Tianjin 300170, China.
Jing LiangDepartment of Gastroenterology and Hepatopathy, The Central Hospital of Tianjin University, Tianjin 300170, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide fumarate (TAF) on long-term recurrence and overall survival in patients with hepatitis B cirrhosis-related hepatocellular carcinoma (HCC) who undergo curative radiofrequency ablation (RFA) remains unclear.

aimTo compare the 3-year recurrence and survival rates among HCC patients receiving these three first-line oral anti-hepatitis B virus (anti-HBV) agents after RFA.

methodsThis retrospective cohort study included patients with hepatitis B cirrhosis who were initially diagnosed with HCC at Tianjin Third Central Hospital, China, from August 2018 to December 2020, and had complete clinical data. All patients were followed up for at least 144 weeks. Cox regression analysis was performed to identify independent risk factors for HCC recurrence. Recurrence-free survival was analyzed using Kaplan-Meier curves, and Cox regression models were constructed after adjusting for gamma-glutamyl transferase, alpha-fetoprotein, and Barcelona Clinic Liver Cancer staging.

resultsA total of 319 patients receiving oral anti-HBV therapy were divided into three groups: ETV group (

conclusionAmong patients with hepatitis B cirrhosis-related HCC, TDF and TAF are associated with lower 2-year and 3-year HCC recurrence rates after curative RFA treatment compared with ETV. However, there were no significant differences in 3-year mortality rates between the ETV, TDF, and TAF groups.

Indexed as

Hepatitis B cirrhosisHepatocellular carcinomaHepatocellular carcinoma recurrenceNucleos(t)ide analogueRadiofrequency ablation

Identifiers

PMID41281477
PMCPMC12635674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.